Joseph Hazen, MD
Family Medicine · Cincinnati, OHNPI 1578527206
Payments from drug & device makers
Across 207 payments — averaging $13.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$407
- Novo Nordisk$371
- AbbVie$323
- Sanofi-aventis U.S. LLC$201
- Amgen$173
- Johnson & Johnson$142
- plus $1K from 35 others
What the payments were for
- Food & beverage$2,820100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $407 |
| Novo Nordisk | 29 | $371 |
| AbbVie(2 entities) | 20 | $323 |
| Sanofi-aventis U.S. LLC | 20 | $201 |
| Amgen(2 entities) | 11 | $173 |
| Johnson & Johnson | 11 | $142 |
| Novartis | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $92 |
| Boehringer Ingelheim | 7 | $91 |
| Bayer | 5 | $88 |
| GSK | 6 | $81 |
| AstraZeneca | 6 | $81 |
| Mannkind Corporation | 4 | $68 |
| Abbott | 3 | $67 |
| Pfizer | 4 | $66 |
| Astellas Pharma US Inc | 3 | $44 |
| Antares Pharma, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $33 |
| Tandem Diabetes Care, Inc. | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $26 |
| Alk-abello, Inc | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Cranial Technologies, Inc | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Merck | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Valeritas, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Neuronetics, Inc. | 1 | $10 |
| Cequr Corporation | 1 | $5 |
How this compares
$2,829 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $87,526 |
| EliquisApixaban | 88 | $83,518 |
| TrulicityDulaglutide | 68 | $82,801 |
| JardianceEmpagliflozin | 65 | $80,631 |
| XareltoRivaroxaban | 30 | $30,094 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $24,712 |
| MounjaroTirzepatide | 14 | $24,328 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,394 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $14,425 |
| JanuviaSitagliptin Phosphate | 11 | $14,259 |
| FarxigaDapagliflozin Propanediol | 11 | $13,724 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,201 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $9,033 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 12 | $7,066 |
| Repatha SyringeEvolocumab | 12 | $6,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $407 | $108,19097 claims |
| Novo NordiskOzempic | $371 | $87,52649 claims |
| PfizerEliquis, Paxlovid | $66 | $84,947101 claims |
| Boehringer IngelheimJardiance | $91 | $80,63165 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $81 | $39,88678 claims |
| Johnson & JohnsonXarelto | $142 | $30,09430 claims |
| MerckJanuvia | $14 | $14,25911 claims |
| AstraZenecaFarxiga | $81 | $13,72411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.